Utility of human milk oligosaccharides against the perinatal pathogen, group B streptococcus
Active Project Grant Awarded Last action
- Award ID
- R01HD113675
- Recipient
-
Vanderbilt University Medical Center UEI GYLUH9UXHDX5
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,103,387
Award facts
- Assistance listing
- 93.865 Child Health and Human Development Extramural Research
- Completion date 44% complete
- Place of performance
- Forest Hills, TN 37215, USA
Award details come from USAspending.gov.
Description
- Abstract
- Adverse pregnancy outcomes are a global issue that affects more than 50 million people per year. Infections during gestation contribute significantly to adverse pregnancy outcomes, such as preterm birth and neonatal sepsis. Streptococcus agalactiae or group B streptococcus (GBS) is a major cause of ascending vaginal and intrauterine infection during pregnancy. To initiate infection, GBS must colonize the vagina and initiate a robust biofilm to turn the vaginal mucosa into a replicative niche. Subsequently, GBS ascends the reproductive tract in an undefined process to invade the gestational membranes, cross the placenta, and infect the amniotic cavity and the fetus. Currently, there is no commercially available vaccine against GBS to prevent its cognate disease outcomes. However, epidemiological data has indicated that exposure to maternal breast milk is associated with protection against GBS infection of the neonate. We have new and exciting data to suggest that components of human breast milk, such as human milk oligosaccharides (HMOS), have antibiofilm activity against GBS. Given this, we hypothesize that treatment with HMOS could lead to decreased GBS biofilm formation, colonization, invasive infection cognate inflammation, microbiome disruption, and disease progression. We will test this by determining the contribution of HMOS on bacterial and immunological responses in primary human placental macrophages, an organ-on-a-chip infection model, EX vivo gestational membrane model, vaginal tissue models and a mouse model of infection during pregnancy. This work will help US establish the efficacy of deployment of prebiotic HMOS as a cost-effective dietary or chemotherapeutic strategy against GBS which may improve pregnancy outcomes in vulnerable groups.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $353,540 | |
| Amendment | $364,926 | |
| Amendment | $0 | |
| Original award | $384,921 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Louisiana State University | -$345 | |
| Vanderbilt University | $75,670 | |
| Vanderbilt University | $75,670 | |
| Louisiana State University | $14,755 | |
| Louisiana State University | $14,756 | |
| Vanderbilt University | $75,670 |
Quick answers
Who received award R01HD113675?
R01HD113675 was awarded to Vanderbilt University Medical Center by National Institute of Child Health and Human Development (National Institutes of Health) on September 20, 2024.
How much is award R01HD113675 worth?
$1,103,387 has been obligated on R01HD113675.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award